Biotech investor Genoa Ventures, in partnership with True Ventures, Amplify Partners, Boost VC and Prado SV, invested $9.4 million to help develop advance technology accurately detect ovarian cancer at its early stages when it is most curable.
Genoa Ventures has been investing in early-stage life sciences companies innovating at the intersection of biology, technology, and data science. From next-gen genomics platforms to CRISPR-Cas genome editing, it combines an appetite for technology-driven opportunities in life sciences with the domain expertise and operational experience necessary to select and nurture the best bio-based companies early.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.